Sequenom Center for Molecular Medicine Announces Launch of MaterniT21™ Noninvasive Prenatal Test for Down Syndrome

Sequenom, Inc.

today announced that its wholly-owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), launched its noninvasive proprietary MaterniT21 laboratory developed test. The MaterniT21 LDT detects a genetic chromosomal anomaly known as Trisomy 21, the most common cause of Down syndrome. The test is now available to physicians upon request in 20 major metropolitan regions across the United States.